Core Points - A shareholder class action lawsuit has been filed against Replimune Group, Inc. alleging that the company made materially false and misleading statements regarding the IGNYTE trial's prospects [1] - The lawsuit claims that the defendants overstated the trial's prospects despite known material issues, leading the FDA to deem the trial inadequate and not well-controlled [1] - As a result of these actions, the statements made by the defendants about Replimune's business, operations, and prospects were considered materially false and misleading [1] Legal Information - Shareholders who purchased Replimune shares between November 22, 2024, and July 21, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed as lead plaintiff in the case is September 22, 2025 [3] - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. following a significant drop in stock price after the FDA issued a Complete Response Letter regarding its Biologics License Application for RP1 [3][6][7] Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal options [1] - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [3][8] - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4] Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives violated federal securities laws by making false or misleading statements regarding the IGNYTE trial's prospects [5] - It is claimed that the defendants overstated the trial's prospects, leading to the FDA deeming it inadequate and not well-controlled [5][6] - Following the FDA's announcement, Replimune's stock plummeted over 73% during intraday trading on July 22, 2025 [7] Group 3: Company Communication - On July 22, 2025, Replimune announced it received a Complete Response Letter from the FDA, indicating that the application could not be approved in its current form [6] - The FDA's response highlighted that the IGNYTE trial did not provide substantial evidence of effectiveness [6]

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for alleged violations of securities laws, specifically related to misleading statements about the company's clinical trial results [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Replimune's securities between November 22, 2024, and July 21, 2025 [2]. - The Schall Law Firm is representing the investors and encourages those who suffered losses to participate in the lawsuit [5]. Group 2: Allegations Against the Company - The complaint alleges that Replimune made false and misleading statements regarding the IGNYTE trial for RP1 (vusolimogene oderparepvec) [4]. - It is claimed that the company overstated the prospects of the trial and was aware of material issues that could lead to the FDA deeming the trial inadequate [4]. - As a result of these misleading statements, investors experienced financial damages when the truth about the company's situation was revealed [4].

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025 in the securities class action first filed by the Firm. ...

Core Points - The Replimune Group, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934 by the company and its executives during the Class Period from November 22, 2024, to July 21, 2025 [1][3] - The lawsuit claims that Replimune made misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate, leading to a significant drop in stock price [3][4] Company Overview - Replimune is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its lead product candidate being RP1 (vusolimogene oderparepvec) [2] Legal Allegations - The class action lawsuit alleges that Replimune and its executives overstated the prospects of the IGNYTE trial, which resulted in the FDA's Complete Response Letter indicating that the trial was not well-controlled [3][4] - Following the FDA's announcement on July 22, 2025, Replimune's stock price fell by more than 77% [4] Class Action Process - Investors who purchased Replimune securities during the Class Period can seek to be appointed as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]

Core Viewpoint - Replimune Group, Inc. is under investigation for possible securities fraud following a significant stock decline after the FDA's rejection of its Biologics License Application for RP1 [1][3][4] Group 1: Company Overview - Replimune Group, Inc. is a biotechnology company focused on developing treatments for advanced melanoma [3] - The company received a Complete Response Letter (CRL) from the FDA regarding its application for RP1 in combination with nivolumab [3][4] Group 2: Regulatory Developments - The FDA stated that the IGNYTE trial was not adequate for providing substantial evidence of effectiveness, leading to the rejection of the application [4] - The CRL was issued on July 22, 2025, prior to market open [3] Group 3: Market Reaction - Following the FDA announcement, Replimune's stock fell sharply by $9.52 per share, representing a decline of over 77%, closing at $2.80 on July 22, 2025 [4] Group 4: Legal Actions - The Portnoy Law Firm has initiated an investigation and may file a class action on behalf of investors who lost money due to the stock decline [1][2] - Investors are encouraged to contact the law firm for a complimentary case evaluation regarding their legal rights [2][5]

Core Viewpoint - Replimune Group, Inc. is under investigation for potential violations of federal securities laws following a significant decline in stock price after the FDA's response regarding its lead product candidate RP1 [1][4]. Company Overview - Replimune is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with RP1 as its lead product candidate aimed at melanoma [2]. Clinical Trial Results - On June 6, 2024, Replimune announced positive top-line results from the IGNYTE Phase 1/2 clinical trial for RP1 in combination with nivolumab [2]. - The company repeatedly promoted the results of the IGNYTE trial, but the trial design was criticized for not being adequate to produce reliable results [3]. Regulatory Response - On July 22, 2025, Replimune received a Complete Response Letter from the FDA, indicating that the IGNYTE trial was not considered adequate and well-controlled, leading to a significant stock price drop of over 75% [4]. - The FDA specifically noted that the trial's results could not be adequately interpreted due to the heterogeneity of the patient population [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Replimune Group, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Replimune Group, Inc. received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1, indicating that the application cannot be approved in its current form [3]. - The FDA stated that the IGNYTE trial does not provide substantial evidence of effectiveness, which contributed to a significant drop in Replimune's stock price [3]. - Following the announcement of the CRL, Replimune's common stock fell by $9.52 per share, representing a decline of over 77%, closing at $2.80 on July 22, 2025 [3]. Group 2: Legal Action and Investor Rights - Investors who purchased Replimune securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. - The firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Replimune Group, Inc. following a significant stock price drop after the FDA issued a Complete Response Letter regarding its Biologics License Application for RP1 [1][3]. Company Summary - Replimune Group, Inc. (NASDAQ: REPL) faced a major setback when the FDA issued a Complete Response Letter on July 22, 2025, indicating that the application for RP1 in combination with nivolumab for advanced melanoma could not be approved in its current form [3]. - The FDA's letter highlighted that the IGNYTE trial was not considered adequate and well-controlled, lacking substantial evidence of effectiveness due to the heterogeneity of the patient population [3]. - Following the announcement, Replimune's stock price plummeted by $9.52, or 77.24%, closing at $2.81 per share [3]. Legal Investigation - Bragar Eagel & Squire, P.C. is encouraging investors who suffered losses from Replimune's stock decline to contact them to discuss potential legal rights and claims [1][4]. - The law firm is specifically looking into whether Replimune violated federal securities laws or engaged in unlawful business practices [1].

Core Viewpoint - Replimune Group, Inc. is under investigation for potential violations of federal securities laws following a significant decline in its stock price after receiving a Complete Response Letter from the FDA regarding its lead product RP1 [1][3]. Company Summary - Replimune received a Complete Response Letter from the FDA on July 22, 2025, indicating that its IGNYTE trial was not considered adequate for demonstrating the effectiveness of RP1 in combination with nivolumab for advanced melanoma [3]. - Following the FDA's announcement, Replimune's stock price fell by $9.52, or approximately 77.24%, closing at $2.81 per share [3]. Legal Investigation Summary - Kirby McInerney LLP is investigating potential claims against Replimune and its officers for possible violations of federal securities laws and other unlawful business practices [1][4].